Table 2.

Comparative Cytotoxicity of BO-1978 with Therapeutic Agents in NSCLC Cells (IC₅₀, μM).^⁎

Cell Line	BO-1978	Cisplatin	Irinotecan	Etoposide	Gefitinib
H460	1.06 ± 0.11	9.94 ± 0.47	4.18 ± 1.29	7.31 ± 2.56	28.41 ± 7.44
A549	3.15 ± 1.20	31.10 ± 3.03	9.29 ± 3.31	22.40 ± 14.39	17.65 ± 1.55
H1299	3.02 ± 0.65	16.53 ± 0.90	24.46 ± 1.85	15.61 ± 7.45	27.87 ± 2.34
CL1-5	1.47 ± 0.53	2.82 ± 0.28	10.53 ± 2.54	12.64 ± 3.93	ND
CL141T	1.32 ± 0.47	2.80 ± 0.36	44.99 ± 15.72	23.32 ± 3.34	20.56 ± 3.34
H1650	3.50 ± 0.10	36.50 ± 8.14	17.05 ± 4.20	32.48 ± 17.56	32.81 ± 1.38
H1975	2.34 ± 0.18	16.09 ± 4.03	36.83 ± 14.43	14.12 ± 2.90	50.72 ± 7.58
CL100	1.51 ± 0.30	6.21 ± 3.64	0.66 ± 0.65	4.30 ± 3.87	27.60 ± 4.70
CL97	1.25 ± 0.18	14.70 ± 0.34	9.99 ± 3.10	24.40 ± 17.39	8.91 ± 1.65
PC9	1.41 ± 0.37	16.35 ± 3.29	11.23 ± 1.97	19.33 ± 6.28	0.29 ± 0.05
PC9/gef B4	1.58 ± 0.33 [1.12]†	34.34 ± 1.62 [2.10]	31.58 ± 4.70 [2.81]	36.66 ± 20.54 [1.90]	25.68 ± 4.68 [88.55]

^⁎IC₅₀, the concentration of drug required to inhibit cell growth by 50% (mean ± S.D. of three independent experiments).

^†Numbers in brackets are the resistance factors of PC9/gef B4 to PC9 cells.